The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access
The United Kingdom has universal healthcare systems, the National Health System (NHS), in its four nations, with healthcare services provided free of charge at the point of delivery. Approximately 10.5% of the UK population has voluntary supplementary private health insurance. While the provision of...
Saved in:
Main Authors: | Adriana M. IVAMA-BRUMMELL (Author), Pilar PINILLA-DOMINGUEZ (Author), Aline N. BIZ (Author) |
---|---|
Format: | Book |
Published: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Medicines pricing and reimbursement: innovation, competitiveness, and access
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
Medicines regulation, pricing and reimbursement in Brazil
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023) -
Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
by: Xia Mingge MPH, et al.
Published: (2023)